Mazdutide (IBI362) Guide: GLP-1/Glucagon Co-Agonist
Innovent Biologics' Next-Gen Weight Loss Compound (2026)
Guide to Mazdutide (IBI362), a novel GLP-1/glucagon dual receptor agonist from Innovent Biologics targeting obesity and fatty liver disease.
Key Biohacking Mechanics
GLP-1 + Glucagon Dual Action
Metabolic Supercharger for Fat Burn
NAFLD / Fatty Liver Potential
Deep Dive: Understanding the Protocol
Navigating sophisticated pharmacology and metabolic enhancement requires meticulous logging and tracking. Whether you are dealing with rapid-acting exogenous compounds, systemic metabolic effects, or novel receptor mechanisms, operating blindly is a recipe for disaster.
By leveraging precise data entry — documenting exact mg/mcg dosages, correlating them to specific subjective side effects (like lethargy, gastric distress, or hyperactivity), and mapping biological outcomes — you transform an experimental chemical protocol into a calculated, predictable biohack.
Safety Through Data Logging
Never rely on memory for high-leverage metabolic or hormonal interventions. Shotlee ensures your entire protocol history is immutably recorded, highly visible, and perfectly charted to prevent accidental overlaps or dosing errors.
Vital Protocol FAQs
How is Mazdutide different from Tirzepatide?
Tirzepatide (Mounjaro/Zepbound) targets GLP-1 and GIP receptors. Mazdutide targets GLP-1 and glucagon receptors instead. Glucagon activation increases energy expenditure and hepatic fat oxidation, which may provide superior liver fat reduction and metabolic benefits.
How do I track this with the Shotlee app?
Shotlee supports comprehensive protocol tracking — log every dose, monitor side effects, track body composition changes, and view your progress with beautiful analytics. Download free on iOS and join thousands of biohackers who take their protocols seriously.
Stop Guessing. Start Tracking.
Join thousands of biohackers, athletes, and metabolic optimizers who log every dose securely with Shotlee.